Boundless Bio (BOLD) Research & Development (2023 - 2026)

Boundless Bio (BOLD) has reported Research & Development for 4 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 19.81% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $42.4 million (down 21.8% YoY), while the FY2025 annual figure was $44.8 million, down 18.86% from the prior year.
• Research & Development retreated to $9.7 million in Q1 2026 per BOLD's latest filing, from $9.8 million in the prior quarter.
• Across five years, Research & Development topped out at $14.7 million in Q2 2024 and bottomed at $9.5 million in Q1 2023.
• Historically, Research & Development has averaged $11.7 million across 4 years, with a median of $11.6 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development jumped 38.16% — and 2025, when it dropped 26.27%.
• Boundless Bio's Research & Development stood at $10.4 million in 2023, then rose by 27.85% to $13.3 million in 2024, then declined by 26.27% to $9.8 million in 2025, then fell by 0.85% to $9.7 million in 2026.
• Business Quant data shows BOLD's Research & Development at $9.7 million in Q1 2026, $9.8 million in Q4 2025, and $10.7 million in Q3 2025.